Modulation of LMNA splicing as a strategy to treat prelamin A diseases
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The alternatively spliced products of LMNA, lamin C and prelamin A (the precursor to lamin A), are produced in similar amounts in most tissues and have largely redundant functions. This redundancy suggests that diseases, such as Hutchinson-Gilford progeria syndrome (HGPS), that are caused by prelamin A-specific mutations could be treated by shifting the output of LMNA more toward lamin C. Here, we investigated mechanisms that regulate LMNA mRNA alternative splicing and assessed the feasibility of reducing prelamin A expression in vivo. We identified an exon 11 antisense oligonucleotide (ASO) that increased lamin C production at the expense of prelamin A when transfected into mouse and human fibroblasts. The same ASO also reduced the expression of progerin, the mutant prelamin A protein in HGPS, in fibroblasts derived from patients with HGPS. Mechanistic studies revealed that the exon 11 sequences contain binding sites for serine/arginine-rich splicing factor 2 (SRSF2), and SRSF2 knockdown lowered lamin A production in cells and in murine tissues. Moreover, administration of the exon 11 ASO reduced lamin A expression in wild-type mice and progerin expression in an HGPS mouse model. Together, these studies identify ASO-mediated reduction of prelamin A as a potential strategy to treat prelamin A-specific diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Splicing-directed therapy in a new mouse model of human accelerated aging
Osorio, F. G., Navarro, C. L., Cadiñanos, J., López-Mejía, I. C., Quirós, P. M., Bartoli, C., Rivera, J., Tazi, J., Guzmán, G., Varela, I., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002847 · Cited by 432
Cited by
Splice-switching antisense oligonucleotides as therapeutic drugs
Havens, M. A., & Hastings, M. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw533 · Cited by 538
Hutchinson-Gilford Progeria Syndrome: A premature aging disease caused by LMNA gene mutations
Gonzalo, S., Kreienkamp, R., & Askjaer, P. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.06.007 · Cited by 324
Hamczyk, M. R., Villa-Bellosta, R., Gonzalo, P., Andrés-Manzano, M. J., Nogales, P., Bentzon, J. F., López-Otín, C., & Andrés, V. (2018) · Circulation · doi:10.1161/circulationaha.117.030856 · Cited by 153
“10 These features were previously observed in knock-in Lmna G609G/G609G and transgenic G608G BAC mouse models 17–19 ; however, in earlier models, these features did not manifest as early or as severely as described here and were not accompanied by atherosclerosis development.”
BackgroundMetabolic Dysfunction in Hutchinson–Gilford Progeria Syndrome
Kreienkamp, R., & Gonzalo, S. (2020) · Cells · doi:10.3390/cells9020395 · Cited by 45
“In a different study, an antisense oligonucleotide (ASO) was identified that increased lamin C production while reducing progerin [105].”
Background
Metadata
- Authors
- Lee, J. M., Nobumori, C., Tu, Y., Choi, C., Yang, S. H., Jung, H.-J., Vickers, T. A., Rigo, F., Bennett, C. F., Young, S. G., & Fong, L. G.
- Venue
- Journal of Clinical Investigation
- Published
- 2016-03-21
- Volume
- 126
- Issue
- 4
- Pages
- 1592-1602
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2311161794
- Cited by
- 111
- References
- 1
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.